Research Study

A Phase II Multi-center, Single Arm, Safety and Efficacy Study of MBG453 in Combination With Azacitidine and Venetoclax for the Treatment of Acute Myeloid Leukemia (AML) in Adult Patients Unfit for Chemotherapy
Principal Investigator 
David Sanford

Overview

Body Locations and Systems 
Leukemia
Disorders and Conditions 
Acute Myeloid Leukemia
ClinicalTrials.gov# 
NCT04150029
Status 
Recruiting
Study Start/End 
Oct 29, 2020 to Oct 31, 2027
Locations 
Vancouver General Hospital
Name/Title 
Edward Wong, Research Coordinator
Phone 
604-875-4111 ext.22966
Purpose of Study 

The purpose of this study is to investigate the safety and efficacy of the drug MBG453 as treatment for newly diagnosed Acute Myeloid Leukemia patients when used in combination with other anti-cancer treatments.

Eligibility 

Visit ClinicalTrials.gov for more information.

Disclaimer 

Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific research studies only. If you have specific questions which require clinical expertise, please call your primary care physician.